CN104039980A - 精子蛋白作为早期卵巢癌的检测生物标记物 - Google Patents

精子蛋白作为早期卵巢癌的检测生物标记物 Download PDF

Info

Publication number
CN104039980A
CN104039980A CN201280054743.6A CN201280054743A CN104039980A CN 104039980 A CN104039980 A CN 104039980A CN 201280054743 A CN201280054743 A CN 201280054743A CN 104039980 A CN104039980 A CN 104039980A
Authority
CN
China
Prior art keywords
patient
gene
level
ovarian cancer
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280054743.6A
Other languages
English (en)
Chinese (zh)
Inventor
维基·马丁·卡斯特
马丽佐·芝里瓦·因特拉提
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of CN104039980A publication Critical patent/CN104039980A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201280054743.6A 2011-09-15 2012-09-12 精子蛋白作为早期卵巢癌的检测生物标记物 Pending CN104039980A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161535309P 2011-09-15 2011-09-15
US61/535,309 2011-09-15
PCT/US2012/054914 WO2013040071A2 (en) 2011-09-15 2012-09-12 Sperm protein as a detection biomarker of early stage ovarian cancer

Publications (1)

Publication Number Publication Date
CN104039980A true CN104039980A (zh) 2014-09-10

Family

ID=47883948

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280054743.6A Pending CN104039980A (zh) 2011-09-15 2012-09-12 精子蛋白作为早期卵巢癌的检测生物标记物

Country Status (7)

Country Link
US (1) US20150110897A1 (enExample)
EP (1) EP2756100A4 (enExample)
JP (1) JP2014527816A (enExample)
CN (1) CN104039980A (enExample)
CA (1) CA2848578A1 (enExample)
IN (1) IN2014CN02496A (enExample)
WO (1) WO2013040071A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104807997A (zh) * 2015-05-05 2015-07-29 南京格耀生物科技有限公司 一种基于化学发光法检测ca125和sp17含量的试剂盒及方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405077B2 (en) * 2001-02-26 2008-07-29 Albany Medical College Sperm protein 17 for the diagnosis and treatment of cancer
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AT501348B1 (de) * 2005-01-31 2008-10-15 Vitateq Biotechnology Gmbh Verfahren zur tumordiagnose
CN100334110C (zh) * 2005-09-01 2007-08-29 中国人民解放军南京军区南京总医院 一种精子蛋白单克隆抗体及其制备方法和用途
PL1951283T3 (pl) * 2005-11-16 2010-12-31 Pantarhei Bioscience Bv Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. MICHAEL STRAUGHN, JR ET AL: "EXPRESSION OF SPERM PROTEIN 17 (Sp17) IN OVARIAN CANCER", 《INT. J. CANCER》 *
LEONARDO MIRANDOLA ET AL: "Cancer Testis Antigens: Novel Biomarkers and Targetable Proteins for Ovarian Cancer", 《INTERNATIONAL REVIEWS OF IMMUNOLOGY》 *

Also Published As

Publication number Publication date
CA2848578A1 (en) 2013-03-21
WO2013040071A2 (en) 2013-03-21
EP2756100A2 (en) 2014-07-23
JP2014527816A (ja) 2014-10-23
US20150110897A1 (en) 2015-04-23
WO2013040071A3 (en) 2013-05-10
EP2756100A4 (en) 2015-05-13
IN2014CN02496A (enExample) 2015-06-19

Similar Documents

Publication Publication Date Title
JP5697448B2 (ja) 膀胱癌の検出のための新規なマーカー
KR101437718B1 (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
WO2016020710A1 (en) Method of determining pik3ca mutational status in a sample
JP2014036672A (ja) 新しい癌マーカー
JP2017508442A (ja) Ｍｄｍ２阻害剤に対する感受性と関連する遺伝子シグネチャー
TW201300777A (zh) 預測大腸直腸癌轉移復發之生物標記
CN108738329A (zh) 前列腺癌预后方法
JP2007501002A (ja) 癌治療の成功の可能性を予測するための方法及びキット
ES3036448T3 (en) A dna-methylation test for prostate cancer
WO2016118670A1 (en) Multigene expression assay for patient stratification in resected colorectal liver metastases
JP2022528182A (ja) 神経膠腫の診断用または予後予測用の組成物、及びそれに係わる情報を提供する方法
CN102471799B (zh) Tivozanib应答预测
WO2010124265A1 (en) Polymorphisms in angiogenesis pathway genes associated with tumor recurrence in surgery treated cancer patients
CN110023510A (zh) 作为卵巢癌预后诊断标志物的mmp1基因转录产物和检测方法
WO2013144202A1 (en) Biomarkers for discriminating healthy and/or non-malignant neoplastic colorectal cells from colorectal cancer cells
JP2023537870A (ja) 肺がんを診断及び監視するためのバイオマーカー
US20120108445A1 (en) Vegf and vegfr1 gene expression useful for cancer prognosis
CN104039980A (zh) 精子蛋白作为早期卵巢癌的检测生物标记物
CN109642257B (zh) 药物疗法对癌的效果的预测方法
KR102384992B1 (ko) 대장암 환자의 연령 특이적 바이오마커 및 이의 용도
CA3025089C (en) Determination of genetic predisposition to aggressive prostate cancer
EP2978861A2 (en) Unbiased dna methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer
JP2025039500A (ja) 子宮内膜がん患者の臨床的転帰を予測する方法、予測装置、予測プログラム、検査試薬、及び検査キット
US20140005064A1 (en) Polymorphisms in angiogenesis pathway genes associated with tumor recurrence in surgery treated cancer patients
JP2023142853A (ja) 筋層非浸潤性膀胱がんの再発または筋層浸潤性膀胱がんへの進展のリスクの判定方法およびそれに用いるマーカー遺伝子

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140910